Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 4Not yet recruiting 3Active not recruiting 2Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3Lymphoid 1

Conditions

Glioma 2Lymphoma, Follicular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 20Magnetic Resonance Spectroscopy 10Radiotherapy 9Blood Specimen Collection 8pembrolizumab 6Cyclophosphamide 6Bevacizumab 6AZD 6244 6Radiation 5Specimen Handling 4vorasidenib 3fludarabine 3cemiplimab 3aflutinib 3Surgical Procedures, Operative 3Saline Solution 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pemetrexed 3Granulocyte-Macrophage Colony-Stimulating Factor 3tislelizumab 2osimertinib 2naxitamab 2gallium maltolate 2fludarabine phosphate 2dinutuximab 2Topotecan 2Standard of Care 2Spinal Puncture 2Receptors, Interleukin-8B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × vorasidenib × CNS × Clear all
NCT07629089 2026-06-05

VALIENT

University of Pittsburgh

Phase 1 Not yet recruiting
24 enrolled
CNS

Brain Neoplasms, Glioma

NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
408 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT06969352 2025-05-13

VICTORIA

Servier (Tianjin) Pharmaceutical Co. LTD.

Not yet recruiting
60 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡